• Meropenem Workflows for Infection and Resistance Models

  2026-08-22

  Build reproducible Meropenem assays for Gram-negative infection models, susceptibility testing, time-kill studies, and resistance surveillance. This practical guide connects β-lactam pharmacology with controlled workflows, formulation checks, and troubleshooting for research-only applications.

• MK-1775 Workflow for Wee1 Checkpoint Assays

  2026-08-21

  Use MK-1775 to connect Wee1 inhibition with CDC1 Tyr15 dephosphorylation, G2 checkpoint abrogation, and treatment response. This workflow separates proliferative arrest from true cell killing, improving interpretation of combination studies in p53-deficient tumor models.

• LC-MS/MS Metabolomics Reveals CPE Resistance Signatures

  2026-08-21

  The reference study combines LC-MS/MS profiling with supervised machine learning to distinguish carbapenemase-producing Enterobacterales from non-CPE isolates using antibiotic-free metabolic signatures. Its biomarker panel and pathway analysis suggest a route toward faster resistance detection while also clarifying why metabolic state should be interpreted as an associated phenotype rather than definitive proof of mechanism.

• Nadolol (SQ-11725): PK-Aware Study Design

  2026-08-20

  Nadolol (SQ-11725) is a powerful tool for linking beta-adrenergic receptor biology with exposure, tissue distribution, and transporter context. This guide develops a disease-state, compartment-aware workflow for cardiovascular research rather than repeating a conventional beta-blocker overview.

• Caspase-3 Assay: From Mechanism to Translation

  2026-08-20

  A mechanistic and translational guide to using DEVD-dependent caspase-3 activity as a decision-grade endpoint in apoptosis research, with practical guidance for applying the Caspase-3 Fluorometric Assay Kit.

• Anlotinib: VEGFR2 Inhibition and Tumor Angiogenesis

  2026-08-19

  The reference study established anlotinib as a highly potent, relatively selective VEGFR2 tyrosine kinase inhibitor whose dominant preclinical effect is suppression of tumor angiogenesis rather than direct tumor-cell cytotoxicity. Its integrated biochemical, endothelial, ex vivo, and xenograft experiments provide a useful framework for interpreting vascular-targeted cancer research and designing follow-up assays.

• Precision Apoptosis Research with Caspase-3/7 Inhibitor I

  2026-08-19

  A translational perspective on using selective, reversible caspase-3/7 inhibition to distinguish executioner activity from upstream apoptosis signaling in infection, cancer research, and cell-based assay development.

• DAPI in IDD: From Nuclei to Assay Decisions

  2026-08-18

  DAPI staining can do more than label nuclei: it helps researchers separate membrane integrity, nuclear morphology, and cell-state interpretation in intervertebral disc degeneration models. This article presents a decision-oriented workflow for using DAPI Solution (1 mg/mL) alongside mechanistic assays of NP-cell senescence and macrophage polarization.

• 2-APB Workflows for ER Calcium Signaling

  2026-08-18

  2-APB enables rapid, pharmacological dissection of ER calcium release, calcium oscillations, SOCE, and downstream autophagy–apoptosis transitions. This guide translates a Bombyx mori starvation study into practical dosing, imaging, endpoint, and troubleshooting workflows while highlighting the compound’s important TRPC-related limitations.

• Amphotericin B: Ergosterol as an Assay Lever

  2026-08-17

  Explore how Amphotericin B converts fungal membrane sterol biology into a practical assay variable. This guide connects polyene mechanism, ergosterol-dependent synergy, immune signaling, and experimental design for more interpretable fungal infection research.

• PTEN mRNA: From Mechanism to Melanoma Translation

  2026-08-17

  PTEN restoration is moving from a genetic concept to a delivery-and-biology challenge. This thought-leadership guide examines how EZ Cap™ Human PTEN mRNA can support mechanistic cancer research, controlled mRNA transfection and expression, and translational studies inspired by emerging HA-LNP melanoma research.

• Podophyllotoxin: Reading Cell-Cycle Phenotypes

  2026-08-16

  Podophyllotoxin is a powerful cell cycle arrest agent for mechanistic cancer biology. This article presents an interpretation-first framework that separates microtubule disruption, apoptosis, and protective autophagy, using recent hepatocellular carcinoma research to improve assay decisions.

• 4–95, Nrf2, and Neuronal Ferroptosis in AD

  2026-08-15

  The reference study identifies compound 4–95 as a selective Keap1–Nrf2 protein–protein interaction inhibitor that protects neuronal models from ferroptosis and improves cognitive outcomes in an Aβ42-induced mouse model. Its main contribution is linking pharmacological Nrf2 activation to suppression of the Keap1–Nrf2–GPX4 axis, reduced amyloid and tau pathology, and functional behavioral rescue.

• Arctigenin at the Macrophage–Tumor Signaling Interface

  2026-08-14

  A translational framework for evaluating (-)-Arctigenin as a mechanistic probe of macrophage extracellular vesicle signaling, NF-κB activity, iNOS expression, and breast cancer progression—without confusing pathway convergence with clinical proof.

• 2-APB for ER Calcium Signaling Workflows

  2026-08-14

  Build reproducible calcium-release assays with 2-APB, a cell-permeable modulator suited to IP3R, SOCE, and TRPC investigations. This workflow connects calcium imaging with autophagy, calpain, apoptosis, and oxidative injury readouts while highlighting selectivity limits and practical troubleshooting.

7582 records 1/506 page Next 12345 下5页 Last page